Loading…

Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives

Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral saf...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 1995-08, Vol.84 (8), p.927-932
Main Authors: Rajewski, Roger A., Traiger, George, Bresnahan, James, Jaberaboansar, Parinaz, Stella, Valentino J., Thompson, Diane O.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823
cites cdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823
container_end_page 932
container_issue 8
container_start_page 927
container_title Journal of pharmaceutical sciences
container_volume 84
creator Rajewski, Roger A.
Traiger, George
Bresnahan, James
Jaberaboansar, Parinaz
Stella, Valentino J.
Thompson, Diane O.
description Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.
doi_str_mv 10.1002/jps.2600840805
format article
fullrecord <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jps_2600840805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915498594</els_id><sourcerecordid>ark_67375_WNG_2WLQKL6H_9</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</originalsourceid><addsrcrecordid>eNqFkMFuEzEQhi0EKqFw5YbkA9cNtndt7x6rkLZABEEB9Wh57TG4dXYjexO6r8WD8Ey42iiIA-Jk2fP945kPoZeUzCkh7M3tLs2ZIKSuSE34IzSjnJFCECofo1kGWFHyqnmKnqV0SwgRhPMzdCZ5Lkk-Q9_WEYLf-k7HEW-0g2HEy4MOez34vsO9w2sdoRsg6hBGfGEz6lO-gsWbfXC9DndjwMvhO0T862exGE3oLdwP0Xf4LUR_yI0OkJ6jJ06HBC-O5zn6ern8srguVp-u3i0uVoWpuOCFzBOWtasNE1JaA9bld2I5p6KyIE0FLTBBa85dU3LKdduyqm2bVhvJWc3KczSf-prYpxTBqV3027ycokQ9CFNZmPojLAdeTYHdvt2CPeFHQ7n--ljXyejgou6MTyesFKykvM5YM2E_fIDxP5-q9-vNXyMUU_ZB7P0pq-OdErKUXN18vFLsZvX5w0pcqybz9cRDFnnwEFUyHrpsy0cwg7K9_9e2vwFyb6hg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</title><source>Wiley-Blackwell Journals</source><creator>Rajewski, Roger A. ; Traiger, George ; Bresnahan, James ; Jaberaboansar, Parinaz ; Stella, Valentino J. ; Thompson, Diane O.</creator><creatorcontrib>Rajewski, Roger A. ; Traiger, George ; Bresnahan, James ; Jaberaboansar, Parinaz ; Stella, Valentino J. ; Thompson, Diane O.</creatorcontrib><description>Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600840805</identifier><identifier>PMID: 7500275</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>Animals ; Anticoagulants - toxicity ; Biological and medical sciences ; Blood Urea Nitrogen ; Chromatography, Thin Layer ; Cyclodextrins - administration &amp; dosage ; Cyclodextrins - toxicity ; Cyclodextrins - urine ; Dextran Sulfate - toxicity ; Drug toxicity and drugs side effects treatment ; Erythrocytes - drug effects ; Excipients - administration &amp; dosage ; Excipients - metabolism ; Excipients - toxicity ; Hemolysis - drug effects ; Humans ; In Vitro Techniques ; Injections, Intraperitoneal ; Kidney - pathology ; Male ; Medical sciences ; Mice ; Mice, Inbred Strains ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Partial Thromboplastin Time ; Pharmacology. Drug treatments</subject><ispartof>Journal of pharmaceutical sciences, 1995-08, Vol.84 (8), p.927-932</ispartof><rights>1995 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1995 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</citedby><cites>FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600840805$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600840805$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3623158$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7500275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rajewski, Roger A.</creatorcontrib><creatorcontrib>Traiger, George</creatorcontrib><creatorcontrib>Bresnahan, James</creatorcontrib><creatorcontrib>Jaberaboansar, Parinaz</creatorcontrib><creatorcontrib>Stella, Valentino J.</creatorcontrib><creatorcontrib>Thompson, Diane O.</creatorcontrib><title>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.</description><subject>Animals</subject><subject>Anticoagulants - toxicity</subject><subject>Biological and medical sciences</subject><subject>Blood Urea Nitrogen</subject><subject>Chromatography, Thin Layer</subject><subject>Cyclodextrins - administration &amp; dosage</subject><subject>Cyclodextrins - toxicity</subject><subject>Cyclodextrins - urine</subject><subject>Dextran Sulfate - toxicity</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Erythrocytes - drug effects</subject><subject>Excipients - administration &amp; dosage</subject><subject>Excipients - metabolism</subject><subject>Excipients - toxicity</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Injections, Intraperitoneal</subject><subject>Kidney - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Partial Thromboplastin Time</subject><subject>Pharmacology. Drug treatments</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNqFkMFuEzEQhi0EKqFw5YbkA9cNtndt7x6rkLZABEEB9Wh57TG4dXYjexO6r8WD8Ey42iiIA-Jk2fP945kPoZeUzCkh7M3tLs2ZIKSuSE34IzSjnJFCECofo1kGWFHyqnmKnqV0SwgRhPMzdCZ5Lkk-Q9_WEYLf-k7HEW-0g2HEy4MOez34vsO9w2sdoRsg6hBGfGEz6lO-gsWbfXC9DndjwMvhO0T862exGE3oLdwP0Xf4LUR_yI0OkJ6jJ06HBC-O5zn6ern8srguVp-u3i0uVoWpuOCFzBOWtasNE1JaA9bld2I5p6KyIE0FLTBBa85dU3LKdduyqm2bVhvJWc3KczSf-prYpxTBqV3027ycokQ9CFNZmPojLAdeTYHdvt2CPeFHQ7n--ljXyejgou6MTyesFKykvM5YM2E_fIDxP5-q9-vNXyMUU_ZB7P0pq-OdErKUXN18vFLsZvX5w0pcqybz9cRDFnnwEFUyHrpsy0cwg7K9_9e2vwFyb6hg</recordid><startdate>199508</startdate><enddate>199508</enddate><creator>Rajewski, Roger A.</creator><creator>Traiger, George</creator><creator>Bresnahan, James</creator><creator>Jaberaboansar, Parinaz</creator><creator>Stella, Valentino J.</creator><creator>Thompson, Diane O.</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199508</creationdate><title>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</title><author>Rajewski, Roger A. ; Traiger, George ; Bresnahan, James ; Jaberaboansar, Parinaz ; Stella, Valentino J. ; Thompson, Diane O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Animals</topic><topic>Anticoagulants - toxicity</topic><topic>Biological and medical sciences</topic><topic>Blood Urea Nitrogen</topic><topic>Chromatography, Thin Layer</topic><topic>Cyclodextrins - administration &amp; dosage</topic><topic>Cyclodextrins - toxicity</topic><topic>Cyclodextrins - urine</topic><topic>Dextran Sulfate - toxicity</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Erythrocytes - drug effects</topic><topic>Excipients - administration &amp; dosage</topic><topic>Excipients - metabolism</topic><topic>Excipients - toxicity</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Injections, Intraperitoneal</topic><topic>Kidney - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Partial Thromboplastin Time</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rajewski, Roger A.</creatorcontrib><creatorcontrib>Traiger, George</creatorcontrib><creatorcontrib>Bresnahan, James</creatorcontrib><creatorcontrib>Jaberaboansar, Parinaz</creatorcontrib><creatorcontrib>Stella, Valentino J.</creatorcontrib><creatorcontrib>Thompson, Diane O.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rajewski, Roger A.</au><au>Traiger, George</au><au>Bresnahan, James</au><au>Jaberaboansar, Parinaz</au><au>Stella, Valentino J.</au><au>Thompson, Diane O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1995-08</date><risdate>1995</risdate><volume>84</volume><issue>8</issue><spage>927</spage><epage>932</epage><pages>927-932</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>Parenteral administration of β-cyclodextrin (β-CD) results in renal and/or local toxicity dependent on the mode of administration. In an attempt to alleviate these properties, a series of anionically charged sulfoalkyl ether cyclodextrin (SAE-β-CD) derivatives have been developed. The parenteral safety of these derivatives was determined by survival of male mice after intraperitoneal (ip) injection, kidney histopathology, plasma urea nitrogen levels of mice determined 24h after injection, relativein vitrohemolytic potential and activated partial thromboplastin times (APTT). In addition, the 24-h renal excretion behavior of the derivatives was measured. Where appropriate, the results obtained with these cyclodextrin derivatives were compared with results obtained for β-CD and (hydroxypropyl)-β-cyclodextrin (HP-β-CD). The SAE-β-CD derivatives did not produce mortality in mice following ip injection at doses exceeding 5.45 mmol/kg. No significant histological lesions were observed in the kidney tissue of mice receiving the cyclodextrin derivatives. The SAE-β-CD derivatives were excreted faster and to a greater extent than β-CD and at rates comparable to HP-β-CD. The hemolytic potential of these derivatives was less than that of β-CD and comparable to or better than that of HP-β-CD. The SAE-β-CD derivatives did not increase APTT clotting times indicating that these derivatives have no significant anticoagulant activity. The toxicological profile of these derivatives suggests that these molecules may have application as biologically safe β-CD derivatives.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>7500275</pmid><doi>10.1002/jps.2600840805</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 1995-08, Vol.84 (8), p.927-932
issn 0022-3549
1520-6017
language eng
recordid cdi_crossref_primary_10_1002_jps_2600840805
source Wiley-Blackwell Journals
subjects Animals
Anticoagulants - toxicity
Biological and medical sciences
Blood Urea Nitrogen
Chromatography, Thin Layer
Cyclodextrins - administration & dosage
Cyclodextrins - toxicity
Cyclodextrins - urine
Dextran Sulfate - toxicity
Drug toxicity and drugs side effects treatment
Erythrocytes - drug effects
Excipients - administration & dosage
Excipients - metabolism
Excipients - toxicity
Hemolysis - drug effects
Humans
In Vitro Techniques
Injections, Intraperitoneal
Kidney - pathology
Male
Medical sciences
Mice
Mice, Inbred Strains
Miscellaneous (drug allergy, mutagens, teratogens...)
Partial Thromboplastin Time
Pharmacology. Drug treatments
title Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A02%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20Safety%20Evaluation%20of%20Parenterally%20Administered%20Sulfoalkyl%20Ether%20%CE%B2-Cyclodextrin%20Derivatives&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Rajewski,%20Roger%20A.&rft.date=1995-08&rft.volume=84&rft.issue=8&rft.spage=927&rft.epage=932&rft.pages=927-932&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.2600840805&rft_dat=%3Cistex_cross%3Eark_67375_WNG_2WLQKL6H_9%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4565-700638f8c2677dcedfc450d55164de7c4ebe261855f93515abb24bb9bac752823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/7500275&rfr_iscdi=true